The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.136, no.6, pp.803-809, 2010 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 136 Issue: 6
- Publication Date: 2010
- Doi Number: 10.1007/s00432-009-0720-3
- Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.803-809
- Keywords: Colorectal cancer, Irinotecan, XPD, XRCC1, Single nucleotide polymorphisms, Overall survival, MULTIVARIATE-ANALYSIS, STRAND BREAKS, CANCER, CHEMOTHERAPY, GENE, REPAIR, CAPECITABINE, OXALIPLATIN, COMBINATION, TOXICITY
- Akdeniz University Affiliated: Yes
Abstract
Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC).